Related Experiment Video
Updated: Aug 20, 2025

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
Erectile dysfunction in hypertensive males in Kenya: a tertiary referral hospital experience
Malcolm C Correia1, Elijah N Ogola2, Joshua K Kayima2
1University of Nairobi, College of Health Sciences, East African Kidney Institute, Nairobi, Kenya.
Abstract:
Erectile dysfunction (ED) in males can be organic or/and psychological.
Objective:
To determine the burden of ED among adult hypertensive men attending ambulatory clinic at Kenyatta National Hospital, Nairobi, Kenya.
Methods:
Descriptive cross-sectional study on patients on antihypertensive medications, followed for ≥ one month. The tools used were five-item International Index of Erectile Function (IIEF-5) for ED and Alcohol Use Disorders Identification Test for alcohol use.
Results:
Among 385 patients, the mean age was 56.2 ±11.3 years, median follow up in medical clinic was 5 years. The mean body mass index was 26.3 ± 4.6 kg/m2, 209(54.3%) were pre-obese/obese. Current smokers were 76(19.7%) while 133(34.5%) were former smokers. Alcohol use in the past year was reported by 256(68.5%), while hazardous alcohol intake was in 54(14%). Prescribed antihypertensives in various combinations included angiotensin converting enzyme inhibitors/angiotensin receptor blockers to 292(75.8%), calcium channel blockers to 238(61.8%), beta blockerso 129(33.5%) and thiazide diuretics on 77(20%). Using IIEF-5 tool, the prevalence of ED was 364(94.5%) (95%CI 92.2-96.6) distributed as mild in 255(70%), moderate 76(21.9%) and 33(9.1%) severe.
Conclusion:
The burden of ED is high among hypertensive males. Precipitants of ED like cigarette smoking and alcohol use and use of antihypertensives which can cause ED are prevalent too.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Hypertension III: Clinical Manifestations and Diagnostic Studies
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Hypertension I: Introduction
Hypertension II: Pathophysiology
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...

